Gapped 2' modified oligonucleotides
CA 2126691 C · Owner: Isis Pharmaceuticals, Inc. · Inventors: Monia, Brett P.; Cook, Phillip Dan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand and subsequences of 2'-, deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes for, modulating protein in organisms; and for the diagnosis detection and , treatment of other conditions susceptible to antisense therapeutics.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1992 and granted May 6, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.